Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc., which is listed as a subsidiary in the exhibit) on October 30, 2019, reporting events occurring on October 25, 2019. The filing details a significant amendment to the company's existing credit facility.
Key Financial Metrics and Debt Structure
The filing focuses on the restructuring of the company's debt obligations rather than operational financial performance metrics like revenue or profit.
- Total Facility Increase: The credit facility capacity was increased by $15,000,000.
- Amended Revolver: Increased to $100,000,000 (down from $105,000,000).
- Amended Term Loan: Increased to $120,000,000 (up from $100,000,000).
- Maturity Date: Both facilities mature on October 25, 2022.
- Repayment Terms: The Amended Term Loan requires increased quarterly payments of $3,000,000, with the remainder due at maturity.
- Interest Rates: Based on the Total Leverage Ratio, rates are Prime + 0.25% to 2.50% or Eurodollar + 1.25% to 3.50%.
Material Changes Versus Prior Period
The primary material change is the Sixth Amendment to the Credit Agreement, which altered the composition and leverage covenants of the debt:
- Facility Composition: Shifted from a $105M Revolver/$100M Term Loan structure to a $100M Revolver/$120M Term Loan structure.
- Leverage Covenant: The Maximum Total Leverage Ratio was increased from 4.5 to 5.0 for the remainder of fiscal year 2020. It is scheduled to decrease to 4.75 by Q1 2021 and step down by 25 basis points per quarter thereafter, reaching 3.5 by Q2 2022.
- Fixed Charge Coverage: No change; the requirement remains at less than 1.2 to 1.0.
Guidance, Risks, and Contingencies
The filing does not provide operational guidance or management commentary on future revenue or earnings. However, it outlines specific financial risks and contingencies:
- Default Risks: The agreement contains customary events of default that could lead to acceleration of obligations or increased interest rates.
- Collateral: The facility is secured by substantially all personal property assets of Landec and its subsidiaries, excluding Curation Foods' equity interest in Windset Holdings 2010 Ltd.
- Covenant Compliance: The company must adhere to the stepped-down leverage ratio schedule to avoid covenant breaches in future periods.
Important Facts for Investor Verification
- Verify the current outstanding balance on the $100M Revolver and $120M Term Loan to assess actual liquidity usage.
- Confirm the company's current Total Leverage Ratio to ensure compliance with the new 5.0 cap for fiscal year 2020.
- Review the impact of the increased quarterly term loan payments ($3,000,000) on future cash flow projections.
- Note that Lifecore Biomedical, Inc. is a subsidiary of Landec Corporation, not the primary registrant of this filing.